News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Benefits of Crospon’s EndoFLIP(R) System Presented at International Obesity Surgery Congress 2010


9/9/2010 11:29:21 AM

9th September 2010 - Carlsbad & Galway - Crospon, an Irish medical device developer based in Galway, has announced results of a study presented at the 15th Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO 2010), in Long Beach, CA.

The study which took place at the Speciality Surgery Center of Fort Worth, TX, a Center of the AIGB True Results clinical network, the largest gastric band placement network in the world, under the direction of Principal Investigator Dr. Robert G. Snow, demonstrated that 30% of the patients measured achieved greater than 30% excess weight loss in the 4-6 week period after surgery. Even though they had a band adjustment during surgery, no patient required their band to be loosened in the post-operative period.

Crospon develops leading edge minimally invasive medical devices for monitoring, diagnosis and therapy in the gastroenterology area. Earlier this year Crospon launched its EndoFLIP® product in the U.S. market at the 12th World Congress of Endoscopic Surgery in National Harbor, Washington DC. The EndoFLIP® product which received FDA clearance in December 2009 is the first product of its kind, which allows a bariatric surgeon to measure and set a consistent gastric band stoma size during surgery.

Commenting, Dr. Robert Snow, Principal Investigator said, “The results of this study are changing the way we look at adjusting bands, in that we are no longer waiting until a month after surgery for the patient’s first band adjustment, so that they are now getting on a more aggressive weight loss trajectory straight after surgery. It is generally accepted that early weight loss is a good indicator for longer term success.”

Dr Snow continued, “Further studies are planned to assess whether the EndoFLIP® system can be used in a similar manner for post-operative band adjustment with a goal of reducing the number of adjustments by targeting a more precise adjustment each time”.

Speaking at the Congress, Larry Fulton, VP Sales for the Americas, Crospon said, “We are encouraged by the results of this study, and are currently introducing EndoFLIP® in a number of other leading gastric band centers. This study has shown how gastric band surgery can be improved to get patients losing weight more quickly by bringing science to the band adjustment procedure. Whereas the study used the Allergan LapBand®, the EndoFLIP® may be used with any gastric band. The study clearly demonstrated that improved early weight loss was achieved, but it remains to be seen if this translates into long term weight loss outcomes”.

For Further Information please contact John McGuinness Murray Consultants jmcguinness@murrayconsult.ie 00353 1 498 0361 00353 87 6417451 www.endoflip.com

About Crospon

Established in 2006, Crospon is a medical device company focused on the monitoring and treatment of gastroesophageal reflux disorder (GERD). Company co-founder and CEO, John O’Dea, previously co-founded Caradyne, a respiratory products company which was acquired by Respironics Inc in 2004.

In January Crospon announced the completion of a €2 million round of funding and that the Company’s flagship gastroenterology product, EndoFLIP® had received clearance from the US Food and Drugs Administration (FDA). The EndoFLIP® product was released in the U.S. market in April 2010. During 2009, Crospon announced the establishment of a US operation in Carlsbad, California.

In 2008, Crospon announced that it had completed an additional funding round of €3.5m. This funding was primarily used for the completion of development, manufacturing start-up and preparation to market of the EndoFLIP® system.

Crospon received the 2009 Overall Medical Technology Excellence Award and the Gold Award for Innovation and Research and Development at the Irish Medical Device Association Awards and also won the Innovator of the year category for the Irish Small Firms Association National Business Awards 2010.

The Irish Medical Devices Association (IMDA) is an IBEC group that represents the medical technology sector in Ireland, and the IMDA Industry Excellence Awards are supported by Enterprise Ireland and the IDA. Crospon was also awarded the Connaught Business Achievers Award for 2008 in the ‘Ones to Watch’ category and the company’s Smart Drug Delivery Patch in conjunction with HP was listed in Popular Science’s magazines annual ‘Best of What’s New’ for 2008.

John McGuinness Account Director Murray Consultants Limited Latin Hall Golden Lane Dublin 8 Tel: + 353 1 498 0361 Mobile: + 353 87 6417451 Fax: + 353 1 498 0344 Email: jmcguinness@murrayconsult.ie http://www.murrayconsult.ie


Read at BioSpace.com


comments powered by Disqus
Crospon
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES